Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 4/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | CA7 | P43166 | 2/20 | 0.40 |
| ▸ | CA9 | Q16790 | 2/20 | 0.40 |
| ▸ | TACR1 | P25103 | 3/20 | 0.39 |
| ▸ | PPARA | Q07869 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.36 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.36 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.35 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.35 |
| ▸ | CASR | P41180 | 1/20 | 0.35 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.35 |
| ▸ | CTSS | P25774 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15524705 | 1.00 | CA1 (0.42) | CA1TSHRCA2CA7CA9 | |
| SCHEMBL4570494 | 1.00 | CA1 (0.42) | CA1TSHRCA2CA7CA9 | |
| SCHEMBL18027565 | 0.87 | CA1 (0.41) | CA1TSHRCA2CA7CA9 | |
| SCHEMBL16616685 | 0.87 | CA1 (0.41) | CA1TSHRCA2CA7CA9 | |
| SCHEMBL16820724 | 0.87 | CA1 (0.41) | CA1TSHRCA2CA7CA9 | |
| SCHEMBL716556 | 0.85 | PLA2G10 (0.42) | CA1TSHRCA2CA7CA9 | |
| SCHEMBL7226223 | 0.83 | TDP1 (0.42) | CA1TSHRCA2CA7CA9 | |
| SCHEMBL18413379 | 0.83 | PLA2G10 (0.36) | CA1TSHRKMT2APLA2G10PLA2G2A | |
| SCHEMBL7218954 | 0.82 | CA1 (0.38) | CA1TSHRCA2CA7CA9 | |
| SCHEMBL2569081 | 0.82 | CA1 (0.44) | CA1TSHRCA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230399323-A1 | NOVEL COMPOUND, a-SYNUCLEIN AGGREGATE BINDER, AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-12-14 | — | — | US | disclosed |
| EP-2635587-B1 | 6-ARYLAMINO PYRIDONE CARBOXAMIDE AS MEK INHIBITORS | CENTAURUS BIOPHARMA CO LTD (CN) | 2017-02-15 | — | — | EP | disclosed |
| US-9540396-B2 | 6-arylamino pyridone carboxamide as MEK inhibitors | CENTAURUS BIOPHARMA CO., LTD. (CN) | 2017-01-10 | — | — | US | disclosed |
| US-20150175530-A1 | ANTIBACTERIAL AGENTS | ACHAOGEN, INC. | 2015-06-25 | — | — | US | disclosed |
| US-20140080804-A1 | NOVEL 6-ARYLAMINO PYRIDONE CARBOXAMIDE AS MEK INHIBITORS | CENTAURUS BIOPHARMA CO., LTD. (CN) | 2014-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230399323-A1 | NOVEL COMPOUND, a-SYNUCLEIN AGGREGATE BINDER, AND USE THEREOF | SNCA, PARK7, ATXN2L | CA1 3364/4885TSHR 4548/4885CA2 3080/4885 |
| US-20150175530-A1 | ANTIBACTERIAL AGENTS | MRPL21, ABCB11, LSS | CA1 4596/4885TSHR 4007/4885CA2 3990/4885 |
| US-20140080804-A1 | NOVEL 6-ARYLAMINO PYRIDONE CARBOXAMIDE AS MEK INHIBITORS | MAP3K6, MAP3K1, MAP3K21 | CA1 4861/4885TSHR 3414/4885CA2 3926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.